Skip to main content

Advertisement

Table 2 Descriptive results of socio demographic, treatment related and clinical characteristics of patients on second-line treatment in Amhara region (February 2008 – April 2016)

From: Incidence and predictors of second-line antiretroviral treatment failure among adults living with HIV in Amhara region: a multi-centered retrospective follow-up study

Variable Total
N (%)
Treatment failure
Failure
N (%)
Censored
N (%)
Age
 15–24 105 (10.39) 28 (11.02) 77 (10.17)
 25–34 490 (54.08) 124 (48.82) 366 (48.35)
 35–44 299 (32.71) 74(29.13) 225 (29.72)
  ≥ 45 117(10.37) 28(11.02) 89 (11.76)
Gender
 Female 498 (49.26) 118 (46.46) 380 (50.20)
 Male 513 (50.74) 136 (53.54) 377 (49.80)
BMI(kg/m2)
 < 18.5 395 (39.07) 111 (43.70) 409 (54.03)
 18.5–24.99 538 (53.21) 129 (50.79) 284 (37.52)
 > 25 78 (7.72) 14 (5.51) 64 (8.45)
CD4 count at switch
  ≥ 100 cells/mm3 400 (39.56) 111(43.70) 289 (38.18)
  < 100 cells/mm3 611(60.44) 143 (56.30) 468 (61.82)
Regimen modification
 Yes 435 (43.03) 85 (33.46) 350(46.24)
 No 576 (56.97) 169 (66.54) 407(53.76)
ART adherence
 Good 462 (45.70) 101 (39.76) 361(47.69)
 Fair 196 (19.39) 43 (16.93) 153 (20.21)
 Poor 353 (34.92) 110 (43.31) 243 (32.10)
WHO clinical stage
 I 468 (46.29) 114 (44.88) 354 (46.76)
 II 89 (8.80) 20 (7.87) 69 (9.11)
 III 371 (36.70) 84 (33.07) 287(37.91)
 IV 83 (8.21) 36 (14.17) 47 (6.21)
INH given
 Yes 277 (27.40) 51(20.08) 226 (29.85)
 No 734 (72.60) 203 (79.92) 531(70.15)
Functional status at switch
 Working 856 (84.67) 206 (83.74) 650 (85.87)
 Ambulatory 137 (13.55) 40 (16.26) 97 (12.81)
 bedridden 18 (1.78) 8 (3.25) 10 (1.32)
Opportunistic Infections (OI)
 Yes 78 (7.72) 18 (7.09) 60 (7.93)
 No 933 (92.28) 236 (92.91) 697 (92.07)
Second-line regimen
 ABC-ddI-LPV/r 189 (18.69) 35 (13.78) 154 (20.34)
 TDF-3TC-LPV/r 351 (34.72) 94 (37.01) 257(33.95)
 AZT-3TC-LPV/r 106 (10.48) 37 (14.57) 69 (9.11)
 Othersa 365 (36.10) 88 (34.65) 277(36.59)
  1. a = (ABC-ddI-NFV, AZT-3TC-ATV/r, TDF-3TC-ATV/r, ABC-3TC-LPV/r, and ABC-3TC-ATV/r)